JP2019216716A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019216716A5 JP2019216716A5 JP2019120643A JP2019120643A JP2019216716A5 JP 2019216716 A5 JP2019216716 A5 JP 2019216716A5 JP 2019120643 A JP2019120643 A JP 2019120643A JP 2019120643 A JP2019120643 A JP 2019120643A JP 2019216716 A5 JP2019216716 A5 JP 2019216716A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- biomarker
- cancer
- level
- polymorph
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 29
- 150000001875 compounds Chemical class 0.000 claims 19
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 239000000090 biomarker Substances 0.000 claims 14
- 201000011510 cancer Diseases 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 239000013078 crystal Substances 0.000 claims 5
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 238000001574 biopsy Methods 0.000 claims 3
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 229940126062 Compound A Drugs 0.000 claims 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 2
- 229960004942 lenalidomide Drugs 0.000 claims 2
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 2
- 229960000688 pomalidomide Drugs 0.000 claims 2
- 239000013074 reference sample Substances 0.000 claims 2
- 229960003433 thalidomide Drugs 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- ZXWQZGROTQMXME-KMPXOGLXSA-N 2-hydroxy-n-[(e)-3-hydroxy-1-[(3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadec-4-en-2-yl]tetracosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)\C=C\CCCCCCCCCCCCC)COC1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O ZXWQZGROTQMXME-KMPXOGLXSA-N 0.000 claims 1
- RSNPAKAFCAAMBH-UHFFFAOYSA-N 3-(5-amino-2-methyl-4-oxoquinazolin-3-yl)piperidine-2,6-dione Chemical compound CC1=NC2=CC=CC(N)=C2C(=O)N1C1CCC(=O)NC1=O RSNPAKAFCAAMBH-UHFFFAOYSA-N 0.000 claims 1
- IXZOHGPZAQLIBH-UHFFFAOYSA-N 3-[7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1h-isoindol-2-yl]piperidine-2,6-dione Chemical compound O=C1N(C2C(NC(=O)CC2)=O)CC2=C1C=CC=C2OCC(C=C1)=CC=C1CN1CCOCC1 IXZOHGPZAQLIBH-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 102100021069 E3 ubiquitin-protein ligase ZFP91 Human genes 0.000 claims 1
- 101000818429 Homo sapiens E3 ubiquitin-protein ligase ZFP91 Proteins 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 210000002768 hair cell Anatomy 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
Applications Claiming Priority (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361913003P | 2013-12-06 | 2013-12-06 | |
| US61/913,003 | 2013-12-06 | ||
| US201461947963P | 2014-03-04 | 2014-03-04 | |
| US61/947,963 | 2014-03-04 | ||
| US201461990621P | 2014-05-08 | 2014-05-08 | |
| US61/990,621 | 2014-05-08 | ||
| US201462061050P | 2014-10-07 | 2014-10-07 | |
| US62/061,050 | 2014-10-07 | ||
| US201462064413P | 2014-10-15 | 2014-10-15 | |
| US62/064,413 | 2014-10-15 | ||
| US201462077835P | 2014-11-10 | 2014-11-10 | |
| US62/077,835 | 2014-11-10 | ||
| US201462087111P | 2014-12-03 | 2014-12-03 | |
| US62/087,111 | 2014-12-03 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536629A Division JP6573611B2 (ja) | 2013-12-06 | 2014-12-05 | びまん性大細胞型ｂ細胞リンパ腫、多発性骨髄腫、及び骨髄癌の治療の薬効を決定するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019216716A JP2019216716A (ja) | 2019-12-26 |
| JP2019216716A5 true JP2019216716A5 (OSRAM) | 2020-02-13 |
| JP7142612B2 JP7142612B2 (ja) | 2022-09-27 |
Family
ID=53274285
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536629A Active JP6573611B2 (ja) | 2013-12-06 | 2014-12-05 | びまん性大細胞型ｂ細胞リンパ腫、多発性骨髄腫、及び骨髄癌の治療の薬効を決定するための方法 |
| JP2019120643A Active JP7142612B2 (ja) | 2013-12-06 | 2019-06-28 | びまん性大細胞型ｂ細胞リンパ腫、多発性骨髄腫、及び骨髄癌の治療の薬効を決定するための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536629A Active JP6573611B2 (ja) | 2013-12-06 | 2014-12-05 | びまん性大細胞型ｂ細胞リンパ腫、多発性骨髄腫、及び骨髄癌の治療の薬効を決定するための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20160313300A1 (OSRAM) |
| EP (1) | EP3077548B1 (OSRAM) |
| JP (2) | JP6573611B2 (OSRAM) |
| KR (1) | KR102299801B1 (OSRAM) |
| AU (1) | AU2014360328B2 (OSRAM) |
| BR (1) | BR112016012795A2 (OSRAM) |
| CA (2) | CA2932120C (OSRAM) |
| EA (1) | EA201691144A1 (OSRAM) |
| ES (1) | ES2903155T3 (OSRAM) |
| IL (2) | IL278381B2 (OSRAM) |
| MX (1) | MX386337B (OSRAM) |
| PH (1) | PH12016501041A1 (OSRAM) |
| WO (1) | WO2015085172A2 (OSRAM) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102898416A (zh) | 2006-09-26 | 2013-01-30 | 细胞基因公司 | 作为抗肿瘤剂的5-取代的喹唑酮衍生物 |
| SG10201501062SA (en) | 2010-02-11 | 2015-04-29 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| EA026100B1 (ru) | 2011-03-11 | 2017-03-31 | Селджин Корпорейшн | Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2,6-диона и их фармацевтические композиции и применение |
| US9682952B2 (en) | 2012-09-04 | 2017-06-20 | Celgene Corporation | Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl) piperidine-2-6-dione and methods of preparation thereof |
| WO2014116573A1 (en) | 2013-01-22 | 2014-07-31 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| ES2923942T3 (es) | 2013-11-06 | 2022-10-03 | Us Health | Procedimiento para el subtipado de tipos de linfoma por medio de perfiles de expresión |
| EA201691144A1 (ru) | 2013-12-06 | 2016-11-30 | Селджин Корпорейшн | Способы определения эффективности лекарственного средства для лечения диффузной крупноклеточной b-клеточной лимфомы, множественной миеломы и злокачественных новообразований миелоидного ростка |
| JP6640126B2 (ja) | 2014-06-27 | 2020-02-05 | セルジーン コーポレイション | セレブロン及び他のｅ３ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法 |
| ES2901792T3 (es) | 2015-03-31 | 2022-03-23 | Syros Pharmaceuticals Inc | Procedimientos de estratificación de pacientes para el tratamiento con agonistas del receptor del ácido retinoico |
| US10338077B2 (en) | 2015-06-02 | 2019-07-02 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer ration of cereblon associated proteins |
| EP3331613A4 (en) * | 2015-08-04 | 2019-04-17 | Celgene Corporation | METHOD FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA AND USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO IMMUNOMODULATORY THERAPIES |
| EP3334844A4 (en) * | 2015-08-12 | 2019-11-06 | Celgene Corporation | METHOD FOR THE TREATMENT OF SOLID TUMORS AND USE OF BIOMARKERS AS PREDICTORS OF CLINICAL SENSITIVITY TO IMMUNOMODULATORY THERAPIES |
| JP2018529344A (ja) * | 2015-09-25 | 2018-10-11 | セルジーン コーポレイション | びまん性大細胞型ｂ細胞リンパ腫の治療方法及び薬物に対する応答性の予測因子としてのバイオマーカー利用 |
| WO2017100259A1 (en) * | 2015-12-08 | 2017-06-15 | Icahn School Of Medicine At Mount Sinai | Pretransplant prediction of post-transplant acute rejection |
| US10830762B2 (en) * | 2015-12-28 | 2020-11-10 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
| US10648983B2 (en) | 2016-01-08 | 2020-05-12 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
| WO2017143237A1 (en) * | 2016-02-17 | 2017-08-24 | Acetylon Pharmaceuticals, Inc. | Increasing expression of interferon regulated genes with combinatons of histone deacetylase inhibitors and immunomodulatory drugs |
| US9868994B2 (en) | 2016-04-08 | 2018-01-16 | Syros Pharmaceuticals, Inc. | Methods of stratifying patients for treatment with retinoic acid receptor-α agonists |
| CN115737821B (zh) * | 2016-04-08 | 2024-04-12 | 赛罗斯制药有限公司 | 用于治疗aml和mds的rara激动剂 |
| WO2017184861A1 (en) | 2016-04-20 | 2017-10-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Evaluation of mantle cell lymphoma and methods related thereto |
| SG10201607303YA (en) * | 2016-09-01 | 2018-04-27 | Agency Science Tech & Res | Antisense oligonucleotides to induce exon skipping |
| MA46961A (fr) | 2016-12-03 | 2019-10-09 | Juno Therapeutics Inc | Procédés de modulation de lymphocytes t modifiés par car |
| RU2019120398A (ru) | 2016-12-03 | 2021-01-12 | Джуно Терапьютикс, Инк. | Способы определения дозировки cart-клеток |
| US20180238886A1 (en) * | 2017-01-31 | 2018-08-23 | Celgene Corporation | Methods for treating hematological cancer and the use of biomarkers as a predictor for responsiveness to treatment compounds |
| WO2018165482A1 (en) * | 2017-03-10 | 2018-09-13 | Memorial Sloan Kettering Cancer Center | Methods for treatment or prevention of leukemia |
| CA3061945A1 (en) | 2017-05-01 | 2018-11-08 | Juno Therapeutics, Inc. | Combination of a cell therapy and an immunomodulatory compound |
| KR20200054160A (ko) | 2017-06-02 | 2020-05-19 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법 |
| AU2018291032A1 (en) | 2017-06-29 | 2020-01-16 | Juno Therapeutics, Inc. | Mouse model for assessing toxicities associated with immunotherapies |
| WO2019079360A1 (en) * | 2017-10-16 | 2019-04-25 | Massachusetts Institute Of Technology | ATLAS OF HEALTHY AND ILLUMINATED TISSUE CELLS |
| CA3080904A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen |
| WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| WO2019109053A1 (en) | 2017-12-01 | 2019-06-06 | Juno Therapeutics, Inc. | Methods for dosing and for modulation of genetically engineered cells |
| WO2019118937A1 (en) | 2017-12-15 | 2019-06-20 | Juno Therapeutics, Inc. | Anti-cct5 binding molecules and methods of use thereof |
| KR20210018199A (ko) | 2018-03-26 | 2021-02-17 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스의 분해를 위한 세레블론 결합제 |
| CN110448548B (zh) * | 2018-05-08 | 2023-05-05 | 四川大学华西医院 | Ifitm2抑制剂在制备治疗乙型肝炎的药物中的用途 |
| US10969381B2 (en) * | 2018-05-23 | 2021-04-06 | Celgene Corporation | Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile |
| MX2021005366A (es) | 2018-11-08 | 2021-09-10 | Juno Therapeutics Inc | Metodos y combinaciones para el tratamiento y modulacion de celulas t. |
| CA3120118A1 (en) | 2018-11-16 | 2020-05-22 | Juno Therapeutics, Inc. | Methods of dosing engineered t cells for the treatment of b cell malignancies |
| WO2020113194A2 (en) | 2018-11-30 | 2020-06-04 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
| CN109583222A (zh) * | 2018-12-07 | 2019-04-05 | 浪潮(北京)电子信息产业有限公司 | 分布式文件系统元数据服务器回收客户端权限方法及装置 |
| MX2021009087A (es) | 2019-01-29 | 2021-09-08 | Juno Therapeutics Inc | Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1). |
| KR20210152515A (ko) | 2019-04-12 | 2021-12-15 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| WO2020231937A1 (en) * | 2019-05-10 | 2020-11-19 | University Of Massachusetts | Irf2 as a prognostic biomarker and target for augmenting immunotherapy |
| US20220265821A1 (en) * | 2019-07-19 | 2022-08-25 | Pascal Biosciences Inc. | Composition and methods of targeting the pre-b cell receptor for the treatment of leukemias and lymphomas |
| WO2021102420A1 (en) * | 2019-11-22 | 2021-05-27 | The Regents Of The University Of California | Interferon signaling as a cancer biomarker |
| CA3159978A1 (en) * | 2019-12-02 | 2021-06-10 | Celgene Corporation | Therapy for the treatment of cancer |
| US20230042129A1 (en) * | 2019-12-11 | 2023-02-09 | Erasmus University Medical Center Rotterdam | Method for Monitoring of Deep Remissions in Multiple Myeloma and Other Plasma Cell Dyscrasias |
| CN111187755B (zh) * | 2020-02-20 | 2021-10-22 | 中国人民解放军军事科学院军事医学研究院 | 抗tpd52单克隆抗体杂交瘤细胞株及其单克隆抗体与应用 |
| CA3203538A1 (en) | 2020-12-31 | 2022-07-07 | Neil Anthony | Ex vivo systems and methods for determining the effect of a drug or other agent on a tissue |
| WO2022152821A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| CA3209784A1 (en) * | 2021-02-03 | 2022-08-11 | Curis Inc. | Biomarkers for fimepinostat therapy |
| KR102629955B1 (ko) * | 2021-02-19 | 2024-01-25 | 가톨릭대학교 산학협력단 | Ewsr1의 발현 또는 활성 촉진제를 포함하는 비알콜성 지방간염 예방 또는 치료용 약학적 조성물 |
| CN113025720B (zh) * | 2021-04-28 | 2022-12-27 | 深圳市人民医院 | 一种用于检测原发性乳腺弥漫性大b细胞淋巴瘤的标志物及其试剂盒和应用 |
| US20240245664A1 (en) * | 2021-09-08 | 2024-07-25 | The Curators Of The University Of Missouri | Methods of using usp15 inhibitors |
| EP4526469A1 (en) * | 2022-05-16 | 2025-03-26 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
| JP2025521543A (ja) | 2022-06-22 | 2025-07-10 | ジュノー セラピューティクス インコーポレイテッド | Ｃｄ１９標的ｃａｒ ｔ細胞のセカンドライン治療のための処置方法 |
| WO2024097905A1 (en) | 2022-11-02 | 2024-05-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
| WO2025076472A1 (en) | 2023-10-06 | 2025-04-10 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| WO2025164957A1 (ko) * | 2024-01-31 | 2025-08-07 | 남부대학교산학협력단 | 인간화된 세레브론 넉인 마우스 모델 및 이를 이용한 다발성 골수종 항암화학요법의 효능 평가 방법 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| JP3645903B2 (ja) | 1992-03-04 | 2005-05-11 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 比較ゲノムハイブリダイゼーション（ｃｇｈ） |
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| WO2007086915A2 (en) | 2005-05-12 | 2007-08-02 | Applied Genomics, Inc. | Reagents and methods for use in cancer diagnosis, classification and therapy |
| US20070099209A1 (en) | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| US8445198B2 (en) * | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| CL2007002513A1 (es) | 2006-08-30 | 2008-04-04 | Celgene Corp Soc Organizada Ba | Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras. |
| RU2009114745A (ru) | 2006-09-19 | 2010-10-27 | Новартис АГ (CH) | Биомаркеры, предназначенные для выявления направленной модуляции, эффективности ингибиторов raf, применения с целью диагностики и/или прогнозирования |
| US20090148853A1 (en) * | 2007-12-07 | 2009-06-11 | Schafer Peter H | Biomarkers for predicting the sensitivity of cells to immunomodulatory compounds during treatment of non-hodgkin's lymphoma |
| WO2009149319A2 (en) * | 2008-06-05 | 2009-12-10 | Wyeth | Gene expression profiles associated with asthma exacerbation attacks |
| WO2010017515A2 (en) | 2008-08-08 | 2010-02-11 | Integrated Diagnostics Inc. | Breast cancer specific markers and methods of use |
| PE20140963A1 (es) | 2008-10-29 | 2014-08-06 | Celgene Corp | Compuestos de isoindolina para el tratamiento de cancer |
| AU2010236606A1 (en) * | 2009-04-14 | 2011-11-03 | Merck Sharp & Dohme Corp. | Interferon-alfa sensitivity biomarkers |
| US20120134969A1 (en) | 2009-05-25 | 2012-05-31 | Hiroshi Handa | Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells |
| US9217743B2 (en) * | 2009-10-20 | 2015-12-22 | Tokyo Institute Of Technology | Screening method utilizing thalidomide-targeting factor |
| SG10201501062SA (en) * | 2010-02-11 | 2015-04-29 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| CN102959074B (zh) | 2010-04-21 | 2015-06-17 | 普瑞坦医疗产品有限公司 | 采集装置及材料 |
| US20110301102A1 (en) * | 2010-06-07 | 2011-12-08 | Telik, Inc. | Compositions and methods for treating myelodysplastic syndrome |
| CA2829593A1 (en) * | 2011-03-11 | 2012-09-20 | Celgene Corporation | Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases |
| EP2683412B1 (en) * | 2011-03-11 | 2017-05-03 | Mayo Foundation For Medical Education And Research | Methods for assessing responsiveness of cancer cells to lenalidomide, thalidomide, and/or pomalidomide |
| CN103688176A (zh) * | 2011-04-29 | 2014-03-26 | 细胞基因公司 | 利用cereblon作为预报因子治疗癌和炎性疾病的方法 |
| US20130042333A1 (en) * | 2011-05-06 | 2013-02-14 | Jean-Gabriel JUDDE | Markers for cancer prognosis and therapy and methods of use |
| JP2015504677A (ja) | 2012-01-13 | 2015-02-16 | セルジーン コーポレイション | 肝細胞癌治療のためのバイオマーカー |
| ES2872967T3 (es) | 2012-06-29 | 2021-11-03 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS) |
| EP2882442B1 (en) * | 2012-08-09 | 2021-06-09 | Celgene Corporation | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
| TW201526897A (zh) | 2013-04-17 | 2015-07-16 | Signal Pharm Llc | 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法 |
| US20160282354A1 (en) * | 2013-11-08 | 2016-09-29 | The Broad Institute, Inc. | Compositions and methods for selecting a treatment for b-cell neoplasias |
| EA201691144A1 (ru) | 2013-12-06 | 2016-11-30 | Селджин Корпорейшн | Способы определения эффективности лекарственного средства для лечения диффузной крупноклеточной b-клеточной лимфомы, множественной миеломы и злокачественных новообразований миелоидного ростка |
| MX2016007179A (es) | 2013-12-06 | 2016-09-08 | Celgene Corp | Metodos para el tratamiento de canceres hematologicos, y el uso de biomarcadores como predictores de la sensibilidad clinica frente a las terapias inmunomoduladoras. |
| US20170242014A1 (en) | 2014-10-13 | 2017-08-24 | Celgene Corporaton | Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| US10338077B2 (en) | 2015-06-02 | 2019-07-02 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer ration of cereblon associated proteins |
| EP3331613A4 (en) | 2015-08-04 | 2019-04-17 | Celgene Corporation | METHOD FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA AND USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO IMMUNOMODULATORY THERAPIES |
| EP3334844A4 (en) | 2015-08-12 | 2019-11-06 | Celgene Corporation | METHOD FOR THE TREATMENT OF SOLID TUMORS AND USE OF BIOMARKERS AS PREDICTORS OF CLINICAL SENSITIVITY TO IMMUNOMODULATORY THERAPIES |
| JP2018529344A (ja) | 2015-09-25 | 2018-10-11 | セルジーン コーポレイション | びまん性大細胞型ｂ細胞リンパ腫の治療方法及び薬物に対する応答性の予測因子としてのバイオマーカー利用 |
| US10648983B2 (en) | 2016-01-08 | 2020-05-12 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
-
2014
- 2014-12-05 EA EA201691144A patent/EA201691144A1/ru unknown
- 2014-12-05 CA CA2932120A patent/CA2932120C/en active Active
- 2014-12-05 IL IL278381A patent/IL278381B2/en unknown
- 2014-12-05 MX MX2016007239A patent/MX386337B/es unknown
- 2014-12-05 ES ES14868331T patent/ES2903155T3/es active Active
- 2014-12-05 BR BR112016012795A patent/BR112016012795A2/pt not_active Application Discontinuation
- 2014-12-05 US US15/101,869 patent/US20160313300A1/en not_active Abandoned
- 2014-12-05 AU AU2014360328A patent/AU2014360328B2/en active Active
- 2014-12-05 EP EP14868331.1A patent/EP3077548B1/en active Active
- 2014-12-05 CA CA3206268A patent/CA3206268A1/en active Pending
- 2014-12-05 KR KR1020167016778A patent/KR102299801B1/ko active Active
- 2014-12-05 JP JP2016536629A patent/JP6573611B2/ja active Active
- 2014-12-05 WO PCT/US2014/068795 patent/WO2015085172A2/en not_active Ceased
-
2016
- 2016-06-01 PH PH12016501041A patent/PH12016501041A1/en unknown
- 2016-06-01 IL IL245981A patent/IL245981B/en active IP Right Grant
-
2018
- 2018-04-05 US US15/946,618 patent/US10996215B2/en active Active
-
2019
- 2019-06-28 JP JP2019120643A patent/JP7142612B2/ja active Active
-
2021
- 2021-04-01 US US17/220,377 patent/US20220003749A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019216716A5 (OSRAM) | ||
| IL278381B2 (en) | Methods for determining the effectiveness of a drug for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancer | |
| Qian et al. | Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma | |
| Duan et al. | EZH2: a novel target for cancer treatment | |
| Riely et al. | EGFR: the paradigm of an oncogene-driven lung cancer | |
| JP2018535951A5 (OSRAM) | ||
| Gainor et al. | Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer | |
| Nardi et al. | Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment | |
| Chen et al. | Non-small-cell lung cancers: a heterogeneous set of diseases | |
| Neumann et al. | Mutational spectrum of adult T-ALL | |
| Evans et al. | A population of heterogeneous breast cancer patient-derived xenografts demonstrate broad activity of PARP inhibitor in BRCA1/2 wild-type tumors | |
| Sison et al. | Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML | |
| Raparia et al. | Molecular profiling in non–small cell lung cancer: a step toward personalized medicine | |
| Guestini et al. | Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification | |
| JP2018512413A5 (OSRAM) | ||
| Wang et al. | Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers | |
| CN104837491A (zh) | 利用3-(4-((4-(吗啉代甲基)苯甲基)氧基)-1-氧代异二氢吲哚-2-基)哌啶-2,6-二酮治疗癌症的方法 | |
| Hechtman et al. | Identification of targetable kinase alterations in patients with colorectal carcinoma that are preferentially associated with wild-type RAS/RAF | |
| RU2015115151A (ru) | Ингибитор ret | |
| JP2019502669A5 (OSRAM) | ||
| JP2017501400A5 (OSRAM) | ||
| JP2018536636A5 (OSRAM) | ||
| JP2022071077A5 (OSRAM) | ||
| JP2017538104A5 (OSRAM) | ||
| Awada et al. | Targeted therapies of solid cancers: new options, new challenges |